Every 8-K that MapLight Therapeutics, Inc. (MPLT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics, Inc. entered into a private placement with institutional investors to sell 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 shares at $11.38 per share (and $11.3799 per pre-funded warrant), for anticipated gross proceeds of approximately $150.0 million before fees. Each pre-funded warrant is exercisable at $0.0001 per share and does not expire, subject to beneficial ownership limits.
A Registration Rights Agreement requires MapLight to file resale registration statements within 30 days of closing and achieve effectiveness by specified deadlines, with liquidated damages of 1.0% per 30 days on invested amounts if it fails to meet those timelines, subject to caps. Cash, cash equivalents and investments were $351.3 million as of June 30, 2026, and together with the private placement are expected to extend the cash runway through 2028, including projected readouts for the VISTA and ZEPHYR-2 trials.
MapLight reported positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, including meeting the primary PANSS endpoint, a potentially differentiating cognitive signal, and a favorable tolerability profile, supporting advancement into registrational Phase 3 ZEPHYR-2. For the quarter ended June 30, 2026, the company recorded a net loss of $60.2 million, driven by research and development expenses of $53.4 million as it advances its CNS pipeline.
MapLight Therapeutics reported positive topline results from the Phase 2 ZEPHYR trial of ML-007C-MA in adults hospitalized with an acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint, producing a statistically significant and clinically meaningful reduction in PANSS total score versus placebo at Week 5 in the modified intent-to-treat population, with an effect size of 0.37 and a 4.5‑point LS mean improvement (p=0.015). Among trial completers, the effect size was 0.50 with a 6.0‑point LS mean difference (p=0.002), and key secondary endpoints such as CGI‑S and PANSS positive factor also reached significance.
A prespecified cognitive composite endpoint in participants with baseline cognitive impairment showed an effect size of 0.51 (0.44‑point improvement vs placebo; p=0.041) without correlation to PANSS change, suggesting an independent cognitive benefit. ML-007C-MA was generally well tolerated, with no serious or drug‑related severe adverse events, all‑cause discontinuation of 19.9% across active arms, and low rates of GI‑related discontinuations and dose reductions. There were no observed urinary retention, metabolic, hepatic or movement‑related signals, and dosing requires no fasting and only a one‑step titration. MapLight plans an End‑of‑Phase 2 FDA meeting and an additional confirmatory pivotal trial in schizophrenia, while the ongoing VISTA study is evaluating the same 210/3 mg BID dose in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027.
MapLight Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy, indicating strong participation.
Stockholders elected three directors to serve until the 2029 annual meeting. Martin Babler received 31,424,194 votes for and 3,575,737 withheld, Troy Cox received 34,979,012 votes for and 20,919 withheld, and George Pavlov received 34,220,342 votes for and 779,589 withheld, with 1,883,819 broker non-votes.
Stockholders also ratified the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,859,217 votes for, 22,332 against, and 2,201 abstentions.
MapLight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism spectrum disorder. The randomized, placebo-controlled trial enrolled 161 participants, including 102 adolescents and 59 adults.
The study did not meet its primary endpoint of improving the caregiver-reported Autism Behavioral Inventory Social Communication domain. However, in adolescents with moderate or greater baseline irritability (ABC-I >16, N=20), ML-004 showed clinically meaningful reductions in irritability versus placebo on the ABC-I subscale, with a least-squares mean difference of -9.58, effect size 1.33 and nominal p=0.013. A consistent benefit was seen on the clinician-rated CGI-I Irritability domain in the same subgroup, with an effect size of 1.08 and nominal p=0.036.
In the broader group with baseline ABC-I >16 (N=26), the effect size was 0.64 with a nominal p=0.13. ML-004 was generally well-tolerated, with only mild to moderate treatment-emergent adverse events and no severe or serious events reported. MapLight plans to engage the FDA in an End-of-Phase 2 meeting to discuss potential further development of ML-004 for irritability associated with autism, where unmet medical need remains high.
MapLight Therapeutics, Inc. reported that Chief Financial Officer Vishwas Setia separated from the company effective June 18, 2026. The company stated that his departure is wholly unrelated to its financial or operating results, internal controls, clinical programs, or financial reporting practices.
Under a separation agreement, Mr. Setia will receive continued health coverage for himself and his dependents under COBRA for up to three months and has provided a release of claims. The board appointed Jonathan Gillis, the Chief Administrative and Accounting Officer, as interim Chief Financial Officer and interim principal financial officer, while he continues as principal accounting officer.
MapLight Therapeutics reported first quarter 2026 results and highlighted approaching clinical milestones across its CNS portfolio. The company completed enrollment of 307 patients in the Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia and finished last patient visits in the Phase 2 IRIS trial of ML-004 in autism spectrum disorder, with topline data from both studies expected by mid-August 2026. Enrollment is ongoing in the Phase 2 VISTA trial of ML-007C-MA in Alzheimer’s disease psychosis, with topline results targeted for the second half of 2027. Cash, cash equivalents and investments were $395.2 million as of March 31, 2026, which MapLight expects will fund operations through 2027. Research and development expenses rose to $53.7 million from $19.8 million a year earlier and general and administrative expenses increased to $10.8 million from $3.8 million, driving a wider net loss of $60.7 million versus $22.3 million in the prior-year quarter.
MapLight Therapeutics, Inc. reported that directors Robert Malenka, M.D., Ph.D. and Jim Trenkle, Ph.D. have decided not to stand for reelection at the company’s Annual Meeting of Stockholders scheduled for June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace them. The company stated that Dr. Malenka’s and Dr. Trenkle’s decisions were not due to any disagreement with MapLight on its operations, policies, or practices.
MapLight Therapeutics reported a net loss of $161.2 million for 2025, wider than $77.6 million in 2024, as it accelerated clinical development. Research and development expenses rose to $138.3 million from $68.5 million, and general and administrative expenses increased to $30.7 million from $14.4 million.
The company ended 2025 with $453.1 million in cash, cash equivalents and investments and expects this to fund operations through 2027. Total assets were $479.5 million and total liabilities were $21.1 million, resulting in stockholders’ equity of $458.4 million.
MapLight highlighted several near- and mid-term catalysts. Its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia is expected to complete enrollment in April 2026, with topline data in the third quarter of 2026. The Phase 2 IRIS trial of ML-004 in autism spectrum disorder has completed enrollment, also targeting topline data in the third quarter of 2026. ML-007C-MA received FDA Fast Track designation for Alzheimer’s disease psychosis, with Phase 2 VISTA topline results anticipated in the second half of 2027, and the earlier-stage ML-055 program is expected to reach preclinical candidate nomination in 2026.
MapLight Therapeutics disclosed selected preliminary financial information and a development update. For the fiscal year ended December 31, 2025, the company estimates that its cash and cash equivalents were approximately $450 million as of December 31, 2025. This figure is preliminary, unaudited, and may change after completion of year-end closing procedures and the audit of its financial statements.
The company also announced a change in timing for topline data from its ongoing Phase 2 ZEPHYR and IRIS clinical trials, which are now expected in the third quarter of 2026. The cash figure and program updates were included in an updated corporate presentation and a press release furnished as exhibits and made available for investor meetings and on the company’s website.